JUN ZHI Biomedical Co., Ltd
Update：2025/12/03
Industries
Main Industry
Biotechnology
Main Product/Service
CANCER SCREENING PROGRAM FOR DIGESTIVE SYSTEM
Founded Year
2018
Unified Business No.
69764282
Status
Active
Number of Employees
0
Total Paid-in
Capital
105,900,000 (NT$)
Location of Company
Taiwan
, Tainan City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
JUN ZHI Biomedical Co., Ltd. is a biotechnology team from Taiwan, and we have established research and development centers and Operations Center in National Biotechnology Research Park and Tainan Science Park respectively. The technologies authorized by many top research and development units, including Academia Sinica, National Tsing Hua University, National Yang-Ming University and Kaohsiung Medical University, etc. After many years of research and development, we developed the cancer screening service targeted on cancer of digestive system.
The technology of SAA MS screening and interpretation of MS spectra come from Academia Sinica. NTHU is responsible for the development of Magnetic Nanoparticles and antibody for extraction and purification of SAA. NYMU and Metal Industries Research & Development Centre help develop the bio-algorithms, making it more accurate. Last but not least, KMU work on clinical trials and the integration of clinical information to ensurethat SAA nano MS screening service has high accuracy and also help practically in the medical field.
The technology of SAA MS screening and interpretation of MS spectra come from Academia Sinica. NTHU is responsible for the development of Magnetic Nanoparticles and antibody for extraction and purification of SAA. NYMU and Metal Industries Research & Development Centre help develop the bio-algorithms, making it more accurate. Last but not least, KMU work on clinical trials and the integration of clinical information to ensurethat SAA nano MS screening service has high accuracy and also help practically in the medical field.
